Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Fludrocortisone Acetate

FDA-approved product (tablet, oral), marketed as Florinef, Fludrocortisone Acetate.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Fludrocortisone Acetate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Adrenogenital syndrome
  • Chronic primary adrenal insufficiency
  • Primary adrenal insufficiency

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Mineralocorticoids
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA52.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli28.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae26.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis29.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Fludrocortisone Acetate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.3 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.3 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.8 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.0 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Fludrocortisone Acetate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Adaptive Platform Trial for Personnalisation of Sepsis Treatment in Children and Adults: a Multi-national, Treatable Traits-guided, Adaptive, Exploratory, Bayesian Basket Trial

    NCT06381661 · start 2026-07-09

    Registered record
    Registry ID
    NCT06381661
    Conditions
    Sepsis
    Interventions
    Tocilizumab; Baricitinib; Anakinra; Hydrocortisone; Hydrocortisone and fludrocortisone; Heparin; Low molecular weight heparin; Recombinant humanThrombomodulin( rhTM); Sivelestat; Usual care; blood purification with MTx.100 Plasma Adsorption Column; G-CSF filgrastim; Interferon gamma-1b; Fludrocortisone; Prophylactic unfractionated heparin (UFH); Octaplas LG; Plasminogen
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2026-07-09
    Completion
    2031-07-09
    Enrolment
    2,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSepsis
    InterventionTocilizumab; Baricitinib; Anakinra; Hydrocortisone +13 more
    PhasePhase 2
    Registry statusRecruiting

  • A Drug-Drug Interaction Study of Itraconazole and Opevesostat (MK-5684) in Healthy Adult Male Participants (MK-5684-017)

    NCT07548606 · start 2026-05-11

    Registered record
    Registry ID
    NCT07548606
    Conditions
    Healthy
    Interventions
    Opevesostat; Prednisone; Fludrocortisone acetate; Itraconazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2026-05-11
    Completion
    2026-06-18
    Enrolment
    14

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionOpevesostat; Prednisone; Fludrocortisone acetate; Itraconazole
    PhasePhase 1
    Registry statusCompleted

  • Hydrocortisone and Fludrocortisone for the Treatment of Septic Shock

    NCT07383103 · start 2026-03-02

    Registered record
    Registry ID
    NCT07383103
    Conditions
    Septic Shock
    Interventions
    Hydrocortisone plus Fludrocortisone; Standard care
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2026-03-02
    Completion
    2028-12-31
    Enrolment
    336

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSeptic Shock
    InterventionHydrocortisone plus Fludrocortisone; Standard care
    PhasePhase 4
    Registry statusRecruiting

  • FLudrocortisone Administration in Aneurysmal Subarachnoid Haemorrhage

    NCT06409364 · start 2025-08-13

    Registered record
    Registry ID
    NCT06409364
    Conditions
    Aneurysmal Subarachnoid Hemorrhage
    Interventions
    Fludrocortisone; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2025-08-13
    Completion
    2030-07-31
    Enrolment
    524

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAneurysmal Subarachnoid Hemorrhage
    InterventionFludrocortisone; Placebo
    PhasePhase 2
    Registry statusRecruiting

  • A Study to Evaluate Opevesostat (MK-5684) in Male Participants With Moderate Hepatic Impairment (MK-5684-009)

    NCT06860243 · start 2025-05-13

    Registered record
    Registry ID
    NCT06860243
    Conditions
    Hepatic Impairment; Healthy Participants
    Interventions
    Opevesostat; Prednisone; Fludrocortisone acetate
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2025-05-13
    Completion
    2026-02-19
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatic Impairment; Healthy Participants
    InterventionOpevesostat; Prednisone; Fludrocortisone acetate
    PhasePhase 1
    Registry statusCompleted

  • Phase 1 Study of ACE-232 to Treat Patients With Metastatic Castration-Resistant Prostate Cancer

    NCT06801236 · start 2025-05-12

    Registered record
    Registry ID
    NCT06801236
    Conditions
    Prostate Cancer (Adenocarcinoma); mCRPC (Metastatic Castration-resistant Prostate Cancer)
    Interventions
    ACE-232 tablets
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Recruiting
    Start
    2025-05-12
    Completion
    2028-12-31
    Enrolment
    88

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer (Adenocarcinoma); mCRPC (Metastatic Castration-resistant Prostate Cancer)
    InterventionACE-232 tablets
    PhasePhase 1
    Registry statusRecruiting

  • Ramadan Fasting Outcomes in Patients With Secondary Adrenal Insufficiency Before and After the Treatment of Hypotension.

    NCT06832566 · start 2025-02-15

    Registered record
    Registry ID
    NCT06832566
    Conditions
    Secondary Adrenal Insufficiency; Hypotension
    Interventions
    Fludrocortisone 0.1 Milligrams (mg)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Not yet recruiting
    Start
    2025-02-15
    Completion
    2025-04-15
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSecondary Adrenal Insufficiency; Hypotension
    InterventionFludrocortisone 0.1 Milligrams (mg)
    PhasePhase 4
    Registry statusNot yet recruiting

  • A Drug-Drug Interaction Study of Carbamazepine and Opevesostat (MK-5684) in Healthy Adult Male Participants (MK-5684-012)

    NCT06633419 · start 2024-12-18

    Registered record
    Registry ID
    NCT06633419
    Conditions
    Healthy
    Interventions
    Opevesostat; Prednisone; Fludrocortisone acetate; Carbamazepine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2024-12-18
    Completion
    2025-05-13
    Enrolment
    14

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionOpevesostat; Prednisone; Fludrocortisone acetate; Carbamazepine
    PhasePhase 1
    Registry statusCompleted

  • Phase I Study of HSK46575 in Patients With Metastatic Castration-Resistant Prostate Cancer

    NCT07007910 · start 2024-12-18

    Registered record
    Registry ID
    NCT07007910
    Conditions
    m CRPC
    Interventions
    HSK46575
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Recruiting
    Start
    2024-12-18
    Completion
    2026-12
    Enrolment
    90

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    Conditionm CRPC
    InterventionHSK46575
    PhasePhase 1
    Registry statusRecruiting

  • Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)

    NCT06353386 · start 2024-05-20

    Registered record
    Registry ID
    NCT06353386
    Conditions
    Prostatic Neoplasms, Castration-Resistant
    Interventions
    Opevesostat; Olaparib; Docetaxel; Cabazitaxel; Fludrocortisone acetate; Dexamethasone; Prednisone
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Recruiting
    Start
    2024-05-20
    Completion
    2029-01-15
    Enrolment
    220

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstatic Neoplasms, Castration-Resistant
    InterventionOpevesostat; Olaparib; Docetaxel; Cabazitaxel +3 more
    PhasePhase 1 / Phase 2
    Registry statusRecruiting

  • Mechanism-based Therapy of Hypotensive Syncope

    NCT06513650 · start 2024-05-01

    Registered record
    Registry ID
    NCT06513650
    Conditions
    Syncope, Vasovagal, Neurally-Mediated
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2024-05-01
    Completion
    2026-05-31
    Enrolment
    140

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSyncope, Vasovagal, Neurally-Mediated
    InterventionNot recorded
    PhaseNot recorded
    Registry statusUnknown

  • Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)

    NCT06136624 · start 2023-12-31

    Registered record
    Registry ID
    NCT06136624
    Conditions
    Prostate Cancer Metastatic
    Interventions
    Opevesostat; Abiraterone acetate; Enzalutamide; Hydrocortisone; Fludrocortisone acetate; Prednisone; Dexamethasone
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2023-12-31
    Completion
    2030-02-15
    Enrolment
    1,310

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer Metastatic
    InterventionOpevesostat; Abiraterone acetate; Enzalutamide; Hydrocortisone +3 more
    PhasePhase 3
    Registry statusRecruiting

  • A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)

    NCT06136650 · start 2023-12-18

    Registered record
    Registry ID
    NCT06136650
    Conditions
    Metastatic Castration-resistant Prostate Cancer (mCRPC); Prostatic Neoplasms
    Interventions
    Opevesostat; Dexamethasone; Fludrocortisone acetate; Hydrocortisone; Abiraterone acetate; Prednisone acetate; Enzalutamide
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2023-12-18
    Completion
    2030-12-02
    Enrolment
    1,314

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Castration-resistant Prostate Cancer (mCRPC); Prostatic Neoplasms
    InterventionOpevesostat; Dexamethasone; Fludrocortisone acetate; Hydrocortisone +3 more
    PhasePhase 3
    Registry statusRecruiting

  • A Study of Opevesostat (MK-568)4 in Japanese Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-005)

    NCT06104449 · start 2023-11-14

    Registered record
    Registry ID
    NCT06104449
    Conditions
    Prostatic Neoplasms; Metastatic Castration-Resistant Prostate Cancer
    Interventions
    Opevesostat; Dexamethasone; Fludrocortisone acetate; Hydrocortisone
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2023-11-14
    Completion
    2026-04-17
    Enrolment
    7

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstatic Neoplasms; Metastatic Castration-Resistant Prostate Cancer
    InterventionOpevesostat; Dexamethasone; Fludrocortisone acetate; Hydrocortisone
    PhasePhase 1
    Registry statusCompleted

  • Platform of Randomized Adaptive Clinical Trials in Critical Illness

    NCT05440851 · start 2023-04-30

    Registered record
    Registry ID
    NCT05440851
    Conditions
    Respiratory Insufficiency; Extracorporeal Membrane Oxygenation Complication; Mechanical Ventilation Pressure High
    Interventions
    Ultra-Protective Ventilation Facilitated by Extracorporeal Support; Lung-Protective Ventilation (LPV); Driving Pressure-Limited Ventilation (DPL); Lung- and Diaphragm-Protective Ventilation and Sedation (LDPVS); Early Cohort corticosteroid dose; Extended Cohort corticosteroid dose; Usual care without routine corticosteroids; Usual care without extending corticosteroids; Usual care with fludrocortisone; Usual care without fludrocortisone; Drug 4 mL:; Drug 40 mg:; PEEP-20; PEEP-AOP; PEEP-10; VV ECMO-facilitated strategy of earlier awakening, extubation and rehabilitation; Electrical impedance tomography (EIT); no treatment / intervention arm is involved; Usual care; Early Routine IMT; no treatment / intervention arm is involved.
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2023-04-30
    Completion
    2027-03-31
    Enrolment
    6,250

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRespiratory Insufficiency; Extracorporeal Membrane Oxygenation Complication; Mechanical Ventilation Pressure High
    InterventionUltra-Protective Ventilation Facilitated by Extracorporeal Support; Lung-Protective Ventilation (LPV); Driving Pressure-Limited Ventilation (DPL); Lung- and Diaphragm-Protective Ventilation and Sedation (LDPVS) +17 more
    PhaseNot applicable
    Registry statusRecruiting